0
Orphan Designations
2
FDA Approvals
Latest: INQOVI (2020)
2
Active Trials
200 recruiting
4
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Taiho Pharmaceutical Co., Ltd. is a company with 0 orphan drug designations across 4 rare diseases, including 2 FDA-approved therapies. Active clinical trials in 2 indications. 5 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Duchenne muscular dystrophy | - | Des.TrialAppr. |
| cervical cancer | - | Des.TrialAppr. |
| muscular dystrophy | - | Des.TrialAppr. |
| sarcoma | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
54
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
5
affecting portfolio
0% of portfolio targets high unmet need diseases
54
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
5
affecting portfolio